← Back to Patent Explorer
US4751084A Expired / Lapsed US ⏱️ 0.0 years remaining

Tissue plasminogen activator from normal human colon cells

Assignee: Monsanto Co
•
Filing: 1986-11-12
•
Granted: 1988-06-14
•
Expires: 2006-11-12
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Glycosylated plasminogen activator (t-PA) having a glycosylation pattern significantly different than exhibited by t-PA from Bowes melanoma cells is obtained from cultured normal human colon fibroblast cells (CCD-18Co).

Inventors

  • 👤 Joseph Feder
  • 👤 William R. Tolbert
  • 👤 Thomas W. Rademacher
  • 👤 Raj B. Parekh
  • 👤 Raymond A. Dwek

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 12:54
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C08; C08B; C08B37/00; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 49 words
Human tissue plasminogen activator glycoprotein having a glycosylation pattern characteristic of tissue plasminogen activator derived from normal human colon fibroblast cells CCD-18Co (ATCC-1459) grown in nutrient culture medium and being isolated in a highly purified form which is essentially free of other glycoproteins, other cellular components and tissue matter.
Claim 2
Dependent Claim 49 words
Human tissue plasminogen activator glycoprotein having a glycosylation pattern characteristic of tissue plasminogen activator derived from normal human colon fibroblast cells CCD-18Co (ATCC-1459) grown in nutrient culture medium and being isolated in a highly purified form which is essentially free of other glycoproteins, other cellular components and tissue matter.
Claim 3
Dependent Claim 44 words
Human tissue plasminogen activator glycoprotein of claim 1 having a sugar composition comprising oligosaccharides which upon release from the protein moiety and following digestion with neuraminidase exhibit an elution profile upon polyacrylamide gel permeation chromatography substantially as shown in FIG. 5A of the drawings.
Claim 4
Dependent Claim 25 words
Human tissue plasminogen activator glycoprotein of claim 1 in which the sugar moiety has an oligosaccharide composition as shown in FIG. 6 of the drawings.
Claim 5
Dependent Claim 24 words
The tissue plasminogen activator glycoprotein of claim 3 in which the protein moiety of 527 amino acids is glycosylated at Asn-117, Asn-184 and Asn-448.
Claim 6
Dependent Claim 59 words
The tissue plasminogen activator glycoproein of claim 3 in which the percent molar ratio of the individual oligosaccharides is about as follows: ______________________________________ Oligosaccharide Percentage ______________________________________ C-A 1.5 C-B 11.8 C-C-1 11.6 C-C-2 3.0 C-C-3 1.7 C-C-4 1.3 C-D-1 6.0 C-D-2 21.0 C-E 7.3 C-F 3.9 C-G-1 2.3 C-G-2 1.9 C-G-3 2.8 C-H 12.4 C-I 10.9 C-J 1.6 ______________________________________
Claim 7
Dependent Claim 27 words
A therapeutic composition for producing throbolysis comprising a the rapeutically effective amount of the tissue plasminogen activator of claim 1 and a pahramceutically acceptable carrier or diluent.
Claim 8
Dependent Claim 28 words
A method for producing thrombolysis in a patient requiring thrombolytic activity comprising administering to said patient a therapeutically effective amount of the tissue plasminogen activator of claim 1.
Claim 9
Dependent Claim 27 words
Human tissue plasminogen activator glycoprotein of claim 1 in which the protein moiety of 527 amino acids is glycosylated with Type II glycoforms at Asn-117 and Asn-448.
Claim 10
Dependent Claim 28 words
Human tissue plasminogen activator glycoprotein of claim 1 in which the protein moiety of 527 amino acids is glycosylated with Type I glycoforms at Asn-117, Asn-184 and Asn-448.

References Cited (Backward Citations)

US3904470A Cited
US4190708A Cited
EP0041766A2 Cited
US4335215A Cited
GB2119804A Cited
US4505893A Cited
US4537860A Cited
EP0117059A2 Cited
US4550080A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-06-14 1991-12-14 1992-06-14 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-06-14 1995-12-14 1996-06-14 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-06-14 1999-12-14 2000-06-14 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag